Champions Oncology (CSBR) EPS (Weighted Average and Diluted) (2013 - 2026)
Champions Oncology (CSBR) recorded quarterly EPS (Weighted Average and Diluted) of -$0.02 in Q1 2026, down 200.0% quarter-over-quarter from $0.02 in Q4 2025, and down 106.45% on a YoY basis from $0.31 in Q1 2025.
Champions Oncology (CSBR) EPS (Weighted Average and Diluted) (2013 - 2026) Analysis & Trends
Champions Oncology's EPS (Weighted Average and Diluted) history runs 14 years deep, the most recent figure standing at -$0.02 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 106.45% year-over-year to -$0.02; the TTM figure through Jan 2026 stood at -$0.16 (down 136.36% YoY), while the FY2025 annual figure was $0.33, up 161.11% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.02 for Q1 2026 at Champions Oncology, down from $0.02 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.31 in Q1 2025 to a low of -$0.19 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.04 across 5 years, with a median of -$0.02 in 2022.
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) tumbled 12583.1% in 2023, then jumped 263.16% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2022, then plunged by 12583.1% to -$0.15 in 2023, then jumped by 133.33% to $0.05 in 2024, then tumbled by 60.0% to $0.02 in 2025, then tumbled by 200.0% to -$0.02 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.02 (Q1 2026), $0.02 (Q4 2025), and -$0.03 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Champions Oncology | 82.77 Mn | 75.76 Mn | 13.89 Mn | -0.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -0.02 |
| Oct 31, 2025 | 0.02 |
| Jul 31, 2025 | -0.03 |
| Apr 30, 2025 | -0.13 |
| Jan 31, 2025 | 0.31 |
| Oct 31, 2024 | 0.05 |
| Jul 31, 2024 | 0.09 |
| Apr 30, 2024 | -0.01 |
| Jan 31, 2024 | -0.19 |
| Oct 31, 2023 | -0.15 |
| Jul 31, 2023 | -0.19 |
| Apr 30, 2023 | -0.19 |
| Jan 31, 2023 | -0.18 |
| Oct 31, 2022 | 0.00 |
| Jul 31, 2022 | -0.02 |
| Apr 30, 2022 | -0.02 |
| Jan 31, 2022 | 0.05 |
| Oct 31, 2021 | 0.02 |
| Jul 31, 2021 | -0.01 |
| Apr 30, 2021 | -0.05 |